Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 1460491, 11 pages
https://doi.org/10.1155/2017/1460491
Review Article

Update on the Medical Management of Gastrointestinal Behçet’s Disease

1Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
2Institute of Pediatrics, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli 8, 00168 Rome, Italy
3Department of Ophthalmology, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
4Ophthalmology and Neurosurgery Department, University of Siena, Viale Bracci 1, 53100 Siena, Italy
5Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
6Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Viale Bracci 1, 53100 Siena, Italy

Correspondence should be addressed to Luca Cantarini; moc.liamtoh@aculiniratnac

Received 14 September 2016; Accepted 4 January 2017; Published 22 January 2017

Academic Editor: Ronald Gladue

Copyright © 2017 Giuseppe Lopalco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. James, “Behçet's syndrome,” New England Journal of Medicine, vol. 301, no. 8, pp. 431–432, 1979. View at Publisher · View at Google Scholar
  2. V. G. Kaklamani, G. Vaiopoulos, and P. G. Kaklamanis, “Behcet's disease,” Seminars in Arthritis and Rheumatism, vol. 27, no. 4, pp. 197–217, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Behcet's disease,” New England Journal of Medicine, vol. 341, no. 17, pp. 1284–1291, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. D. H. Verity, J. E. Marr, S. Ohno, G. R. Wallace, and M. R. Stanford, “Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives,” Tissue Antigens, vol. 54, no. 3, pp. 213–220, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Cantarini, G. Lopalco, F. Caso et al., “Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease,” Autoimmunity Reviews, vol. 14, no. 1, pp. 1–9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Lopalco, O. M. Lucherini, A. Vitale et al., “Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for Behçet's disease,” Medicine (Baltimore), vol. 94, no. 42, p. e1858, 2015. View at Google Scholar
  7. F. Caso, L. Costa, D. Rigante et al., “Biological treatments in behçet's disease: beyond anti-TNF therapy,” Mediators of Inflammation, vol. 2014, Article ID 107421, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Pineton de Chambrun, B. Wechsler, G. Geri, P. Cacoub, and D. Saadoun, “New insights into the pathogenesis of Behçet's disease,” Autoimmunity Reviews, vol. 11, no. 10, pp. 687–698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Y. Zhou, S. L. Chen, N. Shen, and Y. Lu, “Cytokines and Behcet's disease,” Autoimmunity Reviews, vol. 11, no. 10, pp. 699–704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. P. L. Travis, M. Czajkowski, D. P. B. McGovern, R. G. P. Watson, and A. L. Bell, “Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody,” Gut, vol. 49, no. 5, pp. 725–728, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. P. V. Hassard, S. W. Binder, V. Nelson, and E. A. Vasiliauskas, “Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal behçet's disease: a case report,” Gastroenterology, vol. 120, no. 4, pp. 995–999, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M. T. Kram, L. D. May, S. Goodman, and S. Molinas, “Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy. Report of a case,” Diseases of the Colon and Rectum, vol. 46, no. 1, pp. 118–121, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Hirohata, H. Kikuchi, T. Sawada et al., “Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis,” Modern Rheumatology, vol. 22, no. 3, pp. 405–413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. E. H. Kim, M.-J. Park, S. Park, and E.-S. Lee, “Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease,” Journal of Inflammation (United Kingdom), vol. 12, no. 1, article 41, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Cantarini, A. Vitale, P. Scalini et al., “Anakinra treatment in drug-resistant Behcet’s disease: a case series,” Clinical Rheumatology, vol. 34, no. 7, pp. 1293–1301, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Vitale, D. Rigante, F. Caso et al., “Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory behçet's disease: a case series,” Dermatology, vol. 228, no. 3, pp. 211–214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Cantarini, A. Vitale, M. Borri, M. Galeazzi, and R. Franceschini, “Successful use of canakinumab in a patient with resistant Behçet's disease,” Clinical and Experimental Rheumatology, vol. 30, supplement 72, p. S115, 2012. View at Google Scholar · View at Scopus
  18. Y. Bayraktar, E. Özaslan, and D. H. Van Thiel, “Gastrointestinal manifestations of Behcet's disease,” Journal of Clinical Gastroenterology, vol. 30, no. 2, pp. 144–154, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. I. L. P. Beales, “Gastrointestinal involvement in Behçet's syndrome,” American Journal of Gastroenterology, vol. 93, no. 12, 2633 pages, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. E. Marshall, “Behçet's disease,” Best Practice & Research: Clinical Rheumatology, vol. 18, no. 3, pp. 291–311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. H. Kim and J. H. Cheon, “Intestinal behçet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis?” Yonsei Medical Journal, vol. 57, no. 1, pp. 22–32, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Mendes, M. Correia, M. Barbedo et al., “Behçet's disease—a contemporary review,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 178–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. P. Sfikakis, N. Markomichelakis, E. Alpsoy et al., “Anti-TNF therapy in the management of Behçet's disease—review and basis for recommendations,” Rheumatology, vol. 46, no. 5, pp. 736–741, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. B. E. Sands, “From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation,” Gastroenterology, vol. 126, no. 6, pp. 1518–1532, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. I. J. Choi, J. S. Kim, S. D. Cha et al., “Long-term clinical course and prognostic factors in intestinal Behcet's disease,” Diseases of the Colon and Rectum, vol. 43, no. 5, pp. 692–700, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. C. R. Lee, W. H. Kim, Y. S. Cho et al., “Colonoscopic findings in intestinal Behçet's disease,” Inflammatory Bowel Diseases, vol. 7, no. 3, pp. 243–249, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Cheon and W. H. Kim, “An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease,” Current Opinion in Rheumatology, vol. 27, no. 1, pp. 24–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Yurdakul, N. Tüzüner, I. Yurdakul, V. Hamuryudan, and H. Yazici, “Gastrointestinal involvement in Behçet's syndrome: a controlled study,” Annals of the Rheumatic Diseases, vol. 55, no. 3, pp. 208–210, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Mori, A. Yoshihira, H. Kawamura, A. Takeuchi, T. Hashimoto, and G. Inaba, “Esophageal involvement in Behcet's disease,” The American Journal of Gastroenterology, vol. 78, no. 9, pp. 548–553, 1983. View at Publisher · View at Google Scholar · View at Scopus
  30. E. L. Grigg, S. Kane, and S. Katz, “Mimicry and deception in inflammatory bowel disease and intestinal Behçet disease,” Gastroenterology and Hepatology, vol. 8, no. 2, pp. 103–112, 2012. View at Google Scholar · View at Scopus
  31. L. Ning-Sheng, L. Ruay-Sheng, and T. Kuo-Chih, “High frequency of unusual gastric/duodenal ulcers in patients with Behçet's disease in Taiwan: a possible correlation of MHC molecules with the development of gastric/duodenal ulcers,” Clinical Rheumatology, vol. 24, no. 5, pp. 516–520, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. E. C. Ebert, “Gastrointestinal manifestations of Behçet's disease,” Digestive Diseases and Sciences, vol. 54, no. 2, pp. 201–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. B. Chin and A. S. Kumar, “Behcet colitis,” Clinics in Colon and Rectal Surgery, vol. 28, no. 2, pp. 99–102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. J. S. Kim, S. H. Lim, I. J. Choi et al., “Prediction of the clinical course of Behçet's colitis according to macroscopic classification by colonoscopy,” Endoscopy, vol. 32, no. 8, pp. 635–640, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Chung, J. H. Cheon, S. U. Kim et al., “Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease,” Journal of Clinical Gastroenterology, vol. 44, no. 6, pp. e116–e122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. K. Lee, B. K. Kim, T. I. Kim, and W. H. Kim, “Differential diagnosis of intestinal Behçet's disease and Crohn's disease by colonoscopic findings,” Endoscopy, vol. 41, no. 1, pp. 9–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. H. Cheon, D. S. Han, J. Y. Park et al., “Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease,” Inflammatory Bowel Diseases, vol. 17, no. 2, pp. 605–613, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Hatemi, A. Silman, D. Bang et al., “Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1528–1534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Iida, H. Kobayashi, T. Matsumoto et al., “Postoperative recurrence in patients with intestinal Behçet's disease,” Diseases of the Colon & Rectum, vol. 37, no. 1, pp. 16–21, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. J. H. Lee, T. N. Kim, S. T. Choi et al., “Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab),” Korean Journal of Internal Medicine, vol. 22, no. 1, pp. 24–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Brik, H. Shamali, and R. Bergman, “Successful thalidomide treatment of severe infantile Behçet disease,” Pediatric Dermatology, vol. 18, no. 2, pp. 143–145, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Fallingborg and J. Laustsen, “Colitis of Behçet's syndrome,” Acta Medica Scandinavica, vol. 215, no. 4, pp. 397–399, 1984. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Toda, Y. Shiratori, M. Yusuda et al., “Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçet's disease,” Journal of Gastroenterology, vol. 37, no. 10, pp. 844–848, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. J. J. Park, W. H. Kim, and J. H. Cheon, “Outcome predictors for intestinal Behçet's disease,” Yonsei Medical Journal, vol. 54, no. 5, pp. 1084–1090, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Narum, T. Westergren, and M. Klemp, “Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis,” BMJ Open, vol. 4, no. 5, Article ID e004587, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Kobayashi, F. Ueno, S. Bito et al., “Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach,” Journal of Gastroenterology, vol. 42, no. 9, pp. 737–745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. M. H. Houman and K. Hamzaoui, “Promising new therapies for Behçet's disease,” European Journal of Internal Medicine, vol. 17, no. 3, pp. 163–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Sonta, Y. Araki, M. Kubokawa et al., “The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet's disease,” Journal of Clinical Gastroenterology, vol. 30, no. 2, pp. 195–197, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Matsukawa, T. Yamasaki, T. Kouda, and M. Kurihara, “Endoscopic therapy with absolute ethanol for postoperative recurrent ulcers in intestinal Behçet's disease, and simple ulcers,” Journal of Gastroenterology, vol. 36, no. 4, pp. 255–258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. S. Jung, S. P. Hong, T. I. Kim, W. H. Kim, and J. H. Cheon, “Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease,” Journal of Clinical Gastroenterology, vol. 46, no. 5, pp. e38–e45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Hatemi, S. N. Esatoglu, G. Hatemi, Y. Erzin, H. Yazici, and A. F. Celik, “Characteristics, treatment, and long-term outcome of gastrointestinal involvement in behcet's syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center,” Medicine (United States), vol. 95, no. 16, Article ID e3348, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Sayarlioglu, M. C. Kotan, N. Topcu, I. Bayram, H. Arslanturk, and A. Gul, “Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease,” Annals of Pharmacotherapy, vol. 38, no. 5, pp. 808–811, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. L. Moreira, E. P. Sampaio, A. Zmuidzinas, P. Frindt, K. A. Smith, and G. Kaplan, “Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation,” Journal of Experimental Medicine, vol. 177, no. 6, pp. 1675–1680, 1993. View at Publisher · View at Google Scholar · View at Scopus
  54. B. De Wazières, H. Gil, N. Magy, S. Berthier, D. A. Vuitton, and J. L. Dupond, “Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients,” Revue de Medecine Interne, vol. 20, no. 7, pp. 567–570, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. J. M. M. Gardner-Medwin, N. J. Smith, and R. J. Powell, “Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy,” Annals of the Rheumatic Diseases, vol. 53, no. 12, pp. 828–832, 1994. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Saylan and I. Saltik, “Thalidomide in the treatment of Behçet's syndrome,” Archives of Dermatology, vol. 118, no. 8, 1982. View at Publisher · View at Google Scholar · View at Scopus
  57. M. H. Hamza, “Treatment of Behçet's disease with thalidomide,” Clinical Rheumatology, vol. 5, no. 3, pp. 365–371, 1986. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Bariol, A. P. Meagher, C. R. Vickers et al., “Thalidomide for inflammatory bowel disease: early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease,” Journal of Gastroenterology and Hepatology, vol. 17, no. 2, pp. 135–139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Yasui, N. Uchida, Y. Akazawa et al., “Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease,” Inflammatory Bowel Diseases, vol. 14, no. 3, pp. 396–400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. H. J. Lee, J. H. Cheon, K. J. Lee et al., “Clinical experience of thalidomide in the treatment of korean patients with intestinal Behçet's disease: pilot experience in a single center,” Intestinal Research, vol. 8, no. 1, pp. 63–69, 2010. View at Publisher · View at Google Scholar
  61. I. Hatemi, G. Hatemi, O. N. Pamuk, Y. Erzin, and A. F. Celik, “TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature,” Clinical and Experimental Rheumatology, vol. 33, no. 6, supplement 94, pp. S129–S137, 2015. View at Google Scholar
  62. O. Patey, N. Charasz, A. M. Roucayrol, J. E. Malkin, and C. Lafaix, “Thalidomide and ulcerative colitis in Behçet's disease,” Gastroenterologie Clinique et Biologique, vol. 13, no. 1, article no. 104, 1989. View at Google Scholar · View at Scopus
  63. H. Larsson, “Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217),” Journal of Internal Medicine, vol. 228, no. 4, pp. 405–407, 1990. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Hisamatsu, F. Ueno, T. Matsumoto et al., “The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies,” Journal of Gastroenterology, vol. 49, no. 1, pp. 156–162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. S. Jung, J. H. Cheon, S. P. Hong, T. I. Kim, and W. H. Kim, “Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behçet's disease,” Inflammatory Bowel Diseases, vol. 18, no. 4, pp. 750–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. H. W. Lee, J. H. Cheon, H. J. Lee et al., “Postoperative effects of thiopurines in patients with intestinal Behçet’s disease,” Digestive Diseases and Sciences, vol. 60, no. 12, pp. 3721–3727, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Iwata, K. Saito, K. Yamaoka et al., “Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease,” Modern Rheumatology, vol. 21, no. 2, pp. 184–191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Matsumura, H. Nakase, and T. Chiba, “Efficacy of oral tacrolimus on intestinal Behcet's disease,” Inflammatory Bowel Diseases, vol. 16, no. 2, pp. 188–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. R. C. Wong, C. N. Ellis, and L. A. Diaz, “Behçet's disease,” International Journal of Dermatology, vol. 23, no. 1, pp. 25–32, 1984. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Tsambaos, D. Eichelberg, and M. Goos, “Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon,” Archives of Dermatological Research, vol. 278, no. 4, pp. 335–336, 1986. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Kötter, I. Günaydin, M. Zierhut, and N. Stübiger, “The use of interferon α in Behçet disease: review of the literature,” Seminars in Arthritis and Rheumatism, vol. 33, no. 5, pp. 320–335, 2004. View at Publisher · View at Google Scholar
  72. B. Grimbacher, B. Wenger, P. Deibert, T. Ness, I. Koetter, and H. H. Peter, “Loss of vision and diarrhoea,” Lancet, vol. 350, no. 9094, p. 1818, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Monastirli, E. Chroni, S. Georgiou et al., “Interferon-α treatment for acute myelitis and intestinal involvement in severe Behçet's disease,” QJM, vol. 103, no. 10, pp. 787–790, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. B. Shutty, K. J. Garg, D. Swender, L. Chernin, H. Tcheurekdjian, and R. Hostoffer, “Optimal use of ivig in a patient with Behçet syndrome and common variable immunodeficiency,” Annals of Allergy, Asthma and Immunology, vol. 109, no. 1, article no. 84, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Cantarini, M. L. Stromillo, A. Vitale et al., “Efficacy and safety of intravenous immunoglobulin treatment in refractory Behçet's disease with different organ involvement: a case series,” Israel Medical Association Journal, vol. 18, no. 3-4, pp. 238–242, 2016. View at Google Scholar · View at Scopus
  76. G. Triolo, A. Accardo-Palumbo, F. Dieli et al., “Vγ9/Vδ2 T lymphocytes in Italian patients with Behçet's disease—evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor β1 expression in active,” Arthritis Research and Therapy, vol. 5, no. 5, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Freysdottir, L. Hussain, I. Farmer, S.-H. Lau, and F. Fortune, “Diversity of γδ T cells in patients with Behcet's disease is indicative of polyclonal activation,” Oral Diseases, vol. 12, no. 3, pp. 271–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. N. Pipitone, I. Olivieri, A. Padula et al., “Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature,” Arthritis Care and Research, vol. 59, no. 2, pp. 285–290, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Perra, M. A. Alba, J. L. Callejas et al., “Adalimumab for the treatment of Behçet's disease: experience in 19 patients,” Rheumatology, vol. 51, no. 10, Article ID kes130, pp. 1825–1831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Cantarini, I. Tinazzi, P. Caramaschi, F. Bellisai, A. Brogna, and M. Galeazzi, “Safety and efficacy of etanercept in children with juvenile-onset Behcet's disease,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 551–555, 2009. View at Google Scholar · View at Scopus
  81. R. Caviglia, I. Boškoski, and M. Cicala, “Maintenance treatment with infliximab for the management of Crohn's disease in adults,” Biologics, vol. 3, pp. 39–49, 2009. View at Google Scholar · View at Scopus
  82. H. Ideguchi, A. Suda, M. Takeno et al., “Gastrointestinal manifestations of Behçet's disease in Japan: a study of 43 patients,” Rheumatology International, vol. 34, no. 6, pp. 851–856, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. J. H. Lee, J. H. Cheon, S. W. Jeon et al., “Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study,” Inflammatory Bowel Diseases, vol. 19, no. 9, pp. 1833–1838, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Kinoshita, R. Kunisaki, H. Yamamoto et al., “Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication,” Internal Medicine, vol. 52, no. 17, pp. 1855–1862, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Hibi, S. Hirohata, H. Kikuchi et al., “Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study,” Medicine (United States), vol. 95, no. 24, p. e3863, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Kimura, Y. Tsuji, M. Iwai et al., “Usefulness of adalimumab for treating a case of intestinal Behçet's disease with trisomy 8 myelodysplastic syndrome,” Intestinal Research, vol. 13, no. 2, pp. 166–169, 2015. View at Publisher · View at Google Scholar
  87. T. Mizoshita, S. Tanida, and T. Joh, “Adalimumab treatment in intestinal Behçet's disease: relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement,” Digestive and Liver Disease, vol. 47, no. 11, pp. 991–992, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Della Maggiora, A. Baños, V. Paolini, D. Florio, L. Takashima, and P. Aicardi, “Behçet's disease with intestinal perforation: a case report,” Reumatologia Clinica, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. J. A. M. Van Laar, T. Missotten, P. L. A. Van Daele, A. Jamnitski, G. S. Baarsma, and P. M. Van Hagen, “Adalimumab: a new modality for Behçet's disease?” Annals of the Rheumatic Diseases, vol. 66, no. 4, pp. 565–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. C. De Cassan, B. De Vroey, C. Dussault, E. Hachulla, S. Buche, and J.-F. Colombel, “Successful treatment with adalimumab in a familial case of gastrointestinal Behçet's disease,” Journal of Crohn's and Colitis, vol. 5, no. 4, pp. 364–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Tanida, N. Inoue, K. Kobayashi et al., “Adalimumab for the treatment of japanese patients with intestinal Behçet's disease,” Clinical Gastroenterology and Hepatology, vol. 13, no. 5, pp. 940.e3–948.e3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Tanida, T. Mizoshita, H. Nishie et al., “Long-Term efficacy of adalimumab in patients with intestinal Behçet's disease: eight consecutive cases,” Journal of Clinical Medicine Research, vol. 8, no. 4, pp. 334–337, 2016. View at Google Scholar
  93. S. Watanabe, T. Aizawa-Yashiro, K. Tsuruga, M. Kinjo, E. Ito, and H. Tanaka, “A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent,” Rheumatology International, vol. 33, no. 12, pp. 3105–3108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Ma, C.-J. Zhang, R.-P. Wang, L. Wang, and H. Yang, “Etanercept in the treatment of intestinal Behcet's disease,” Cell Biochemistry and Biophysics, vol. 69, no. 3, pp. 735–739, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Bilginer, N. A. Ayaz, and S. Ozen, “Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease,” Clinical Rheumatology, vol. 29, no. 2, pp. 209–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Botsios, P. Sfriso, A. Furlan, L. Punzi, and C. A. Dinarello, “Resistant Behçet disease responsive to anakinra,” Annals of Internal Medicine, vol. 149, no. 4, pp. 284–286, 2008. View at Google Scholar · View at Scopus
  97. G. Emmi, E. Silvestri, A. M. Cameli et al., “Anakinra for resistant Behçet uveitis: why not?” Clinical and Experimental Rheumatology, vol. 31, no. 77, pp. S152–S153, 2013. View at Google Scholar · View at Scopus
  98. K. Hamzaoui, A. Hamzaoui, F. Guemira, M. Bessioud, M. Hamza, and K. Ayed, “Cytokine profile in Behçet's disease patients: relationship with disease activity,” Scandinavian Journal of Rheumatology, vol. 31, no. 4, pp. 205–210, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Hirano, N. Ohguro, S. Hohki et al., “A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab,” Modern Rheumatology, vol. 22, no. 2, pp. 298–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Cantarini, G. Lopalco, A. Vitale et al., “Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab,” Clinical Rheumatology, vol. 34, no. 6, pp. 1141–1143, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Emmi, E. Silvestri, D. Squatrito, L. Emmi, L. Cantarini, and D. Prisco, “Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet's disease,” Seminars in Arthritis and Rheumatism, vol. 46, no. 1, pp. e1–e2, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Deroux, C. Chiquet, and L. Bouillet, “Tocilizumab in severe and refractory Behcet's disease: four cases and literature review,” Seminars in Arthritis and Rheumatism, vol. 45, no. 6, pp. 733–737, 2016. View at Publisher · View at Google Scholar · View at Scopus
  103. M.-H. Kook, H.-Y. Yhim, N.-R. Lee et al., “Successful treatment of myelodysplastic syndrome and behcet colitis after allogeneic hematopoietic stem cell transplantation,” Korean Journal of Internal Medicine, vol. 29, no. 1, pp. 123–125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. J. K. Ahn, H.-S. Cha, E.-M. Koh et al., “Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8,” Rheumatology, vol. 47, no. 8, pp. 1228–1230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Soysal, A. Salihoğlu, S. N. Esatoğlu et al., “Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature,” Rheumatology, vol. 53, no. 6, pp. 1136–1141, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. S. Jung, J. Y. Yoon, J. H. Lee et al., “Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease,” Inflammatory Bowel Diseases, vol. 17, no. 7, pp. 1594–1602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. C. M. Moon, J. H. Cheon, J. K. Shin et al., “Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings,” Digestive Diseases and Sciences, vol. 55, no. 10, pp. 2904–2911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. I. Sayek, O. Aran, B. Uzunalimoglu, and E. Hersek, “Intestinal Behcet's disease: surgical experience in seven cases,” Hepato-Gastroenterology, vol. 38, no. 1, pp. 81–83, 1991. View at Google Scholar · View at Scopus
  109. S.-J. Chou, V. T.-K. Chen, H.-C. Jan, M. A. Lou, and Y.-M. Liu, “Intestinal perforations in Behçet's disease,” Journal of Gastrointestinal Surgery, vol. 11, no. 4, pp. 508–514, 2007. View at Publisher · View at Google Scholar · View at Scopus